---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Prevalence"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Prevalence. Topics: United States: claims-based prevalence and estimated number of persons, 2023; United States: Olmsted County, Minnesota, population-based prevalence, 2000; United States: accuracy of CIDP diagnosis codes in claims data; Global pooled prevalence: systematic review and meta-analysis; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/prevalence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Chronic inflammatory demyelinating polyneuropathy

<a id="topic-2.2.1.2.2-1"></a>

### United States: claims-based prevalence and estimated number of persons, 2023

> “The adjusted rate was 23.3 (95% CI 23.1–23.5) per 100,000 persons, which corresponds to an estimated 77,058 individuals living with CIDP in the USA in 2023.”
> “corresponding to a raw prevalence rate of 16.8 (95% CI 16.5–17.2) per 100,000 persons”
> “we calculated an adjusted incidence rate of 3.6 per 100,000 persons per year and an adjusted prevalence rate of 18.0 per 100,000 persons to estimate that 58,405 individuals were living with CIDP in the USA in 2019”
> “Furthermore, the medical claim codes used in this study may reflect suspected CIDP and may not represent a confirmed clinical diagnosis of CIDP.”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

<a id="topic-2.2.1.2.2-2"></a>

### United States: Olmsted County, Minnesota, population-based prevalence, 2000

> “The prevalence was 8.9/100,000 persons on January 1, 2000.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

<a id="topic-2.2.1.2.2-3"></a>

### United States: accuracy of CIDP diagnosis codes in claims data

> “The PPV of the algorithm requiring at least one CIDP diagnosis code before IVIG use was 66.2% (95% confidence interval [CI], 58.0-74.3). The PPV improved to 71.2% (62.7-79.6) when requiring at least two CIDP codes before IVIG use. The PPV for patients with at least one CIDP code who met the European Academy of Neurology/Peripheral Nerve Society 2021 diagnostic criteria was 30.0% (22.1-37.9).”

Source: [Okonkwo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40025632/)

<a id="topic-2.2.1.2.2-4"></a>

### Global pooled prevalence: systematic review and meta-analysis

> “the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58–4.39; I2 = 99.1%)”
> “The crude prevalence rate varied between 0.67 and 7.7 cases per 100,000 persons (Table 4).”
> “Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria.”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

<a id="topic-2.2.1.2.2-5"></a>

### Japan: nationwide survey prevalence

> “The primary survey showed that the estimated number of patients with CIDP was 4,180, with a prevalence of 3.3 per 100,000 persons.”
> “The male-to-female ratio was 1.5:1, and the median age at onset was 52 years.”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

<a id="topic-2.2.1.2.2-6"></a>

### South Korea: nationwide claims-based prevalence, 2020

> “The age-adjusted prevalence was estimated at 1.16 per 100,000 persons in 2020.”

Source: [Jung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10622719/)

<a id="topic-2.2.1.2.2-7"></a>

### United States: patients identified among 6.5 million commercial health plan members, 2011

> “CIDP patients from 9 U.S. commercial health plans with claims in 2011 were identified from the Accordant Health Services claims database.”
> “From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria.”

Source: [Guptill et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24639235/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
